Third Rock’s Mark Levin Warns of System-Wide Failure To Support Young Biomedical Companies
This article was originally published in The Pink Sheet Daily
Executive Summary
Third Rock Partner Mark Levin is excited about emerging science, but somewhat pessimistic about the environment for companies pursuing it.
You may also be interested in...
Third Rock Ventures Rolls Its Own
Third Rock Ventures has raised $1.3 billion by going all-in on early-stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitively that the strategy is working, but then again, its investors just re-upped for a new half-billion-dollar fund.
Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality
During a year in which biotech IPOs have taken off, the bluebird bio issue calls for special attention. Plus news on recent financings by Quintiles, Portola, Isis and Lumena.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.